Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1315
- Registration Number
- NCT03187197
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳Mackay Memorial Hospital, Taipei, Taiwan
🇨🇳Show Chwan Memorial Hospital, Changhua, Taiwan
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT03175211
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Japanese Pradaxa PMS, Long Term
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Prazaxa® Capsules
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5660
- Registration Number
- NCT03175198
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd, Tokyo, Japan
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
- Conditions
- NeoplasmsNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT03166631
- Locations
- 🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 114
- Registration Number
- NCT03166735
- Locations
- 🇨🇦
Toronto Liver Centre, Toronto, Ontario, Canada
🇳🇱Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
🇺🇸National Research Institute, Los Angeles, California, United States
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 75
- Registration Number
- NCT03165227
- Locations
- 🇺🇸
Indago Research and Health Center, Hialeah, Florida, United States
🇺🇸Research by Design, LLC, Chicago, Illinois, United States
🇺🇸Houston Clinical Research Associates, Houston, Texas, United States
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
- Conditions
- Diabetic Nephropathies
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT03165240
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
🇩🇰Bispebjerg og Frederiksberg Hospital, København NV, Denmark
🇩🇰Copenhagen University Hospital, Rigshospitalet, København Ø, Denmark
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1351
- Registration Number
- NCT03165045
- Locations
- 🇩🇪
Dr. Urban, Berlin, Germany
🇩🇪Dr. Kassik, Bitterfeld-Wolfen, Germany
🇩🇪Praxis B. Metzlaff, Büchen, Germany
This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT03159455
- Locations
- 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
🇯🇵SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT03157089
- Locations
- 🇫🇷
HOP Côte de Nacre, Caen, France
🇫🇷HOP Le Mans, Le Mans, France
🇺🇸Baptist Health Medical Group, Lexington, Kentucky, United States